CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in...
Read MoreJP Morgan Healthcare Conference 2026
Jan 12 - Jan 15, 2026
San Francisco
Annual Conference on Sarcopenia, Cachexia, and Wasting Disorders 2025
Dec 11 - Dec 13, 2025
Rome, Italy
GDFATHER-01 Trial Long Term Follow-Up: GDF-15 Neutralization Combined With Nivolumab Can Enable Deep, Long-Term Remission In Heavily Pretreated, Anti-PD1/-L1 Relapsed/ Refractory Major Solid Tumor Types
Ignacio Melero Bermejo, María de Miguel Luken, Elena Garralda Cabanas, Guillermo de...
Read MoreCatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025
CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in...
Read MoreCatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO
CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase...
Read MoreCatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in...
Read MoreCatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial in Late-breaking Oral Presentation at ESMO
CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial...
Read MoreCatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development
CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development Experienced...
Read MoreCatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025
CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug...
Read More